{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:57:08Z","timestamp":1779245828571,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02924-0","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:41:27Z","timestamp":1759232487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Puriya Daniel W\u00fcrtz","family":"Yazdanfard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrine Kold","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bochra","family":"Zareini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrik","family":"Pedersen-Bjergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan Sebastian","family":"Ohlendorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Munch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel Porsborg","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus Bo","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Imberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Tasseleus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Lind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Valabhji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratik","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Lanzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Mader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas Alexander","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The REDDIE consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"22","key":"2924_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"1","key":"2924_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1186\/s12885-023-11305-3","volume":"23","author":"JAC Duenas","year":"2023","unstructured":"Duenas JAC, Sanchez PN, Bonilla CE. Comparison of clinical outcomes among cancer patients treated in and out of clinical trials. BMC Cancer. 2023;23(1):786.","journal-title":"BMC Cancer"},{"issue":"2","key":"2924_CR3","first-page":"42","volume":"3","author":"P Blanche","year":"2022","unstructured":"Blanche P, Zareini B, Rasmussen PV. A hazard ratio above one does not necessarily mean higher risk, when using a time-dependent Cox model. Res Methods Med Health Sci. 2022;3(2):42\u20138.","journal-title":"Res Methods Med Health Sci"},{"issue":"2","key":"2924_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/00001648-199303000-00007","volume":"4","author":"Y Wax","year":"1993","unstructured":"Wax Y, Galai N, Carey V, Simchen E. Cox regression models for intermediate events, with discharge from hospital as an example. Epidemiol Camb Mass. 1993;4(2):120\u20137.","journal-title":"Epidemiol Camb Mass"},{"issue":"1","key":"2924_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/EDE.0b013e3181c1ea43","volume":"21","author":"MA Hern\u00e1n","year":"2010","unstructured":"Hern\u00e1n MA. The hazards of hazard ratios. Epidemiol Camb Mass. 2010;21(1):13\u20135.","journal-title":"Epidemiol Camb Mass"},{"key":"2924_CR6","doi-asserted-by":"publisher","first-page":"j4587","DOI":"10.1136\/bmj.j4587","volume":"359","author":"MA Mansournia","year":"2017","unstructured":"Mansournia MA, Etminan M, Danaei G, Kaufman JS, Collins G. Handling time varying confounding in observational research. BMJ. 2017;359:j4587.","journal-title":"BMJ"},{"issue":"2","key":"2924_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1515\/jci-2013-0007","volume":"18","author":"M Petersen","year":"2014","unstructured":"Petersen M, Schwab J, Gruber S, Blaser N, Schomaker M, van der Laan M. Targeted maximum likelihood Estimation for dynamic and static longitudinal marginal structural working models. J Causal Inference. 2014; 18(2):147\u201385.","journal-title":"J Causal Inference"},{"key":"2924_CR8","doi-asserted-by":"crossref","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 ;16(3):232\u201342.","DOI":"10.1056\/NEJMoa1501352"},{"issue":"24","key":"2924_CR9","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n MA, Wang W, Leaf DE. Target trial emulation: A framework for causal inference from observational data. JAMA. 2022;328(24):2446\u20137.","journal-title":"JAMA"},{"key":"2924_CR10","doi-asserted-by":"crossref","unstructured":"Gruber S, Lee H, Phillips R, Ho M, van der Laan M. Developing a Targeted Learning-Based Statistical Analysis Plan. Stat Biopharm Res. 2023;15(3):468\u201375.","DOI":"10.1080\/19466315.2022.2116104"},{"key":"2924_CR11","doi-asserted-by":"publisher","unstructured":"Yazdanfard PD, S\u00f8rensen KK, Consortium TR, Torp-Pedersen C. Statistical analysis plan: Emulation of a Target Trial in an EMPA-REG inspired population using the Danish registries. SGLT2i compared to DPP4i on Cardiovascular outcomes. 2024 July 10 [cited 2024 Dec 16]; Available from: https:\/\/doi.org\/10.5281\/zenodo.12705109","DOI":"10.5281\/zenodo.12705109"},{"key":"2924_CR12","doi-asserted-by":"crossref","unstructured":"Pedersen CB. The Danish civil registration system. Scand J Public Health. 2011;39(7 Suppl):22\u20135.","DOI":"10.1177\/1403494810387965"},{"key":"2924_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/CLEP.S91125","volume":"7","author":"M Schmidt","year":"2015","unstructured":"Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, S\u00f8rensen HT. The Danish National patient registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u201390.","journal-title":"Clin Epidemiol"},{"key":"2924_CR14","doi-asserted-by":"crossref","unstructured":"Kildemoes HW, S\u00f8rensen HT, Hallas J. The Danish National prescription registry. Scand J Public Health. 2011;39(7 Suppl):38\u201341.","DOI":"10.1177\/1403494810394717"},{"key":"2924_CR15","doi-asserted-by":"crossref","unstructured":"Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26\u20139.","DOI":"10.1177\/1403494811399958"},{"key":"2924_CR16","doi-asserted-by":"crossref","unstructured":"Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7_suppl):103\u20135.","DOI":"10.1177\/1403494811405098"},{"key":"2924_CR17","doi-asserted-by":"crossref","unstructured":"Vm J, Aw R. Danish Education Registers. Scand J Public Health [Internet]. 2011 July [cited 2025 Jan 6];39(7 Suppl). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21775362\/","DOI":"10.1177\/1403494810394715"},{"key":"2924_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2147\/CLEP.S245060","volume":"12","author":"JFH Arendt","year":"2020","unstructured":"Arendt JFH, Hansen AT, Ladefoged SA, S\u00f8rensen HT, Pedersen L, Adelborg K. Existing data sources in clinical epidemiology: laboratory information system databases in Denmark. Clin Epidemiol. 2020;12:469\u201375.","journal-title":"Clin Epidemiol"},{"key":"2924_CR19","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2147\/CLEP.S99518","volume":"8","author":"ME J\u00f8rgensen","year":"2016","unstructured":"J\u00f8rgensen ME, Kristensen JK, Reventlov Husted G, Cerqueira C, Rossing P. The Danish adult diabetes registry. Clin Epidemiol. 2016;8:429\u201334.","journal-title":"Clin Epidemiol"},{"key":"2924_CR20","doi-asserted-by":"crossref","unstructured":"van der Laan MJ, Gruber S. Targeted minimum loss based Estimation of causal effects of multiple time point interventions. Int J Biostat. 2012;8(1).","DOI":"10.1515\/1557-4679.1370"},{"key":"2924_CR21","unstructured":"Lam H. A Cheap Bootstrap Method for Fast Inference [Internet]. arXiv; 2022 [cited 2024 Dec 16]. Available from: http:\/\/arxiv.org\/abs\/2202.00090"},{"key":"2924_CR22","doi-asserted-by":"publisher","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","volume":"187","author":"P Paolisso","year":"2023","unstructured":"Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, et al. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry. Pharmacol Res. 2023;187:106597.","journal-title":"Pharmacol Res"},{"issue":"1","key":"2924_CR23","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","volume":"23","author":"P Paolisso","year":"2024","unstructured":"Paolisso P, Belmonte M, Gallinoro E, Scarsini R, Bergamaschi L, Portolan L, et al. SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI). Cardiovasc Diabetol. 2024;23(1):420.","journal-title":"Cardiovasc Diabetol"},{"key":"2924_CR24","doi-asserted-by":"crossref","unstructured":"Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, R\u00f8rth R, Madelaire C et al. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovasc Diabetol. 2020;19(1):107.","DOI":"10.1186\/s12933-020-01078-5"},{"key":"2924_CR25","doi-asserted-by":"crossref","unstructured":"Nystr\u00f6m T, Bodegard J, Nathanson D, Thuresson M, Norhammar A, Eriksson JW. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):831\u201341.","DOI":"10.1111\/dom.12889"},{"key":"2924_CR26","doi-asserted-by":"crossref","unstructured":"Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, J\u00f8rgensen ME, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP\u20134 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol. 2020;8(7):606\u201315.","DOI":"10.1016\/S2213-8587(20)30130-3"},{"key":"2924_CR27","doi-asserted-by":"publisher","first-page":"l4772","DOI":"10.1136\/bmj.l4772","volume":"366","author":"B Pasternak","year":"2019","unstructured":"Pasternak B, Ueda P, Eliasson B, Svensson AM, Franz\u00e9n S, Gudbj\u00f6rnsdottir S, et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. BMJ. 2019;366:l4772.","journal-title":"BMJ"},{"key":"2924_CR28","doi-asserted-by":"publisher","first-page":"928121","DOI":"10.3389\/fphar.2022.928121","volume":"13","author":"HY Jang","year":"2022","unstructured":"Jang HY, Kim IW, Oh JM. Using real-world data for supporting regulatory decision making: comparison of cardiovascular and safety outcomes of an empagliflozin randomized clinical trial versus real-world data. Front Pharmacol. 2022;13:928121.","journal-title":"Front Pharmacol"},{"key":"2924_CR29","unstructured":"Molero-Calafell J, Bur\u00f3n A, Castells X, Porta M. Intention to treat and per protocol analyses: differences and similarities. J Clin Epidemiol [Internet]. 2024 Sept 1 [cited 2024 Dec 16];173. Available from: https:\/\/www.jclinepi.com\/article\/S0895\u20134356%2824%2900213\u20130\/fulltext?utm_source=chatgpt.com"},{"key":"2924_CR30","doi-asserted-by":"crossref","unstructured":"Mo Y, Lim C, Watson JA, White NJ, Cooper BS. Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ. 2020 July 1;m2215.","DOI":"10.1136\/bmj.m2215"},{"issue":"5","key":"2924_CR31","doi-asserted-by":"publisher","first-page":"afab282","DOI":"10.1093\/ageing\/afab282","volume":"51","author":"KH Pitkala","year":"2022","unstructured":"Pitkala KH, Strandberg TE. Clinical trials in older people. Age Ageing. 2022;51(5):afab282.","journal-title":"Age Ageing"},{"issue":"1","key":"2924_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"key":"2924_CR33","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;13(24):2295\u2013306.","DOI":"10.1056\/NEJMoa1811744"},{"issue":"14","key":"2924_CR34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"14","key":"2924_CR35","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"key":"2924_CR36","doi-asserted-by":"crossref","unstructured":"Khunti K, Kosiborod M, Kim DJ, Kohsaka S, Lam CSP, Goh SY, et al. Cardiovascular outcomes with sodium\u2013glucose cotransporter\u20132 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovasc Diabetol. 2021;31(1):159.","DOI":"10.1186\/s12933-021-01345-z"},{"key":"2924_CR37","doi-asserted-by":"crossref","unstructured":"Armillotta M, Angeli F, Paolisso P, Belmonte M, Raschi E, Di Dalmazi G, et al. Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure. Pharmacol Ther. 2025;1:270:108861.","DOI":"10.1016\/j.pharmthera.2025.108861"},{"issue":"5","key":"2924_CR38","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1093\/ehjcvp\/pvaf040","volume":"11","author":"D Fedele","year":"2025","unstructured":"Fedele D, Casuso Alvarez M, Maida A, Vasumini N, Amicone S, Canton L, et al. Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials. Eur Heart J - Cardiovasc Pharmacother. 2025;11(5):441\u201350.","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"key":"2924_CR39","doi-asserted-by":"crossref","unstructured":"van der Laan MJ, Rose S. Targeted Learning in Data Science: Causal Inference for Complex Longitudinal Studies [Internet]. Springer International Publishing; 2018. (Springer Series in Statistics). Available from: https:\/\/books.google.dk\/books?id=vKFTDwAAQBAJ","DOI":"10.1007\/978-3-319-65304-4"},{"key":"2924_CR40","unstructured":"Hernan MA, Robins JM. Causal Inference: What If [Internet]. CRC Press;, Chapman. & Hall\/CRC Monographs on Statistics & Applied Probab). Available from: https:\/\/books.google.dk\/books?id=_KnHIAAACAAJ"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02924-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:41:41Z","timestamp":1759232501000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02924-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2924"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02924-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Competing interests (none for authors if nothing is stated): CTP received study grants in the past 36 months from Bayer and Novo Nordisk. ML received payment to own company for education of diabetes by Boehringer Ingelheim, Novo Nordisk and Eli Lilly. UBP received lecture fees and personal payments by Abott, Novo Nordisk and Sanofi with the addition of EASD meeting support from the latter two. JKM is a member of advisory boards of Abbott Diabetes Care, Becton-Dickinson, Biomea Fusion, Dexcom, Eli Lilly, Embecta, Medtronic, myLife, Novo Nordisk A\/S, Pharmasens, Roche Diabetes Care, Sanofi-Aventis, Tandem, Viatris and received speaker honoraria from A. Menarini Diagnostics, Abbott Diabetes Care, Dexcom, Eli Lilly, Medtrust, MSD, Novo Nordisk A\/S, Roche Diabetes Care, Sanofi, Viatris and Ypsomed. She is a shareholder of decide Clinical Software GmbH and elyte Diagnostics and serves as CMO of elyte Diagnostics. KK has recieved consulting frees and payment as speaker from Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, Servier, Pfizer, Roche, Daiichi-Sankyo, Embecta and Nestle Health Science. With the addition of grants from AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Sanofi, Servier, Oramed Pharmaceuticals, Roche, Daiichi-Sankyo, Applied Therapeutics. JV receives support\/grants from \u2018The north west london NIHR applied research collaboration including other NIHR grants, EU Horizon \/ UKRI grant and CW+ the official charity of Chelsea Westminster hospital NHS foundation trust. Additionally, JV was International Advisor for the Ministry of Public Health in Qatar\u2019s \u201cDiabetes, Obesity and Atherosclerotic Cardiovascular Disease Strategy 2024 to 2030\u201d, for a 3-month period in 2024.PC has received personal fees from Medtronic, Insulet, Dexcom, Abbott, Vertex, Lilly, Novo Nordisk and Sanofi. He has received research support from Abbott, Dexcom, Medtronic, Sanofi and Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"371"}}